Key Points
- CEO Randy Teel sold 9,657 Arvinas shares on May 11 at an average price of $9.94, worth about $95,991. The filing says the sale was made to cover tax withholding tied to vesting equity awards.
- After the transaction, Teel still directly owned 287,218 shares, valued at roughly $2.85 million, and his stake fell by 3.25%. The article also notes he made additional sales earlier in the year.
- Arvinas shares were trading around $9.87 and the company recently reported a narrower-than-expected quarterly loss of -$0.90 per share, though revenue missed estimates and fell sharply year over year.
Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David Loomis sold 1,919 shares of the company's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $19,074.86. Following the completion of the sale, the chief accounting officer directly owned 40,193 shares in the company, valued at $399,518.42. This trade represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Arvinas Price Performance
ARVN stock opened at $9.87 on Thursday. The firm's fifty day simple moving average is $11.14 and its 200-day simple moving average is $11.69. The company has a market capitalization of $636.81 million, a P/E ratio of -2.97 and a beta of 1.79. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $14.51.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.05. The business had revenue of $15.60 million for the quarter, compared to the consensus estimate of $16.61 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business's revenue for the quarter was down 91.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. As a group, sell-side analysts forecast that Arvinas, Inc. will post -3.29 earnings per share for the current year.
Trending Headlines about Arvinas
Here are the key news stories impacting Arvinas this week:
- Positive Sentiment: BTIG Research raised its price target on Arvinas to $18.00 from $16.00 and reiterated a Buy rating, signaling confidence in meaningful upside from current levels. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
- Positive Sentiment: Arvinas and Pfizer’s breast cancer drug VEPPANU (vepdegestrant) was licensed to Rigel Pharmaceuticals, with the deal including $85 million upfront plus up to $320 million in milestones. That provides validation for Arvinas’ PROTAC platform and adds potential future non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
- Neutral Sentiment: Arvinas reported Q1 earnings of -$0.90 per share, slightly better than estimates, but revenue of $15.6 million missed expectations and fell sharply from last year, underscoring that profitability is still distant. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
- Negative Sentiment: CEO Randy Teel, CFO Andrew Saik, CAO David K. Loomis, and insider Noah Berkowitz all sold shares, though the filings indicate the sales were mainly for tax withholding tied to equity vesting. While routine, insider sales can still weigh on sentiment. CEO insider filing
Institutional Investors Weigh In On Arvinas
A number of large investors have recently modified their holdings of the business. ProShare Advisors LLC grew its holdings in shares of Arvinas by 7.2% during the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company's stock worth $176,000 after buying an additional 993 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Arvinas by 3.6% in the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company's stock valued at $278,000 after purchasing an additional 1,125 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company's stock valued at $401,000 after purchasing an additional 1,381 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock valued at $271,000 after purchasing an additional 2,122 shares during the period. Finally, Oxford Asset Management LLP grew its holdings in shares of Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company's stock valued at $123,000 after purchasing an additional 2,242 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on ARVN shares. Barclays upped their price objective on shares of Arvinas from $18.00 to $20.00 and gave the company an "overweight" rating in a report on Wednesday. Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Wedbush boosted their target price on shares of Arvinas from $9.00 to $11.00 and gave the company a "neutral" rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arvinas in a research note on Friday, April 10th. Finally, Citigroup boosted their target price on shares of Arvinas from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Monday, May 4th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $15.14.
View Our Latest Analysis on ARVN
About Arvinas
(
Get Free Report)
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.
The company's most advanced clinical candidates address hormone-driven cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
